Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07475052Enrolling By Invitation

Continuous HRV Monitoring for Predicting Response to Biologic Therapy in IBD

Role: collaborator

NCT06604130Not ApplicableEnrolling By Invitation

Plasma Exosome RNA to Diagnose Prostate Cancer

Role: collaborator

NCT06063941Not ApplicableCompleted

High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal Chromoendoscopy

Role: collaborator

All 3 trials loaded